Ticker: PVCT

Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) Quick read: management is spending to advance clinical programs (PV-10, PH-10, PV-305) while converting portions of convertible debt to preferred stock and raising small tranches of financing. The company faces acute liquidity pressure and a going‑c...